Last updated: March 13, 2026
What is the Composition and Therapeutic Use?
NDC 82009-0040 refers to Nivolumab (Opdivo), a monoclonal antibody used as an immune checkpoint inhibitor targeting programmed death-1 (PD-1). Approved primarily for multiple cancers including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. Its indications have expanded since initial FDA approval in 2014, reflecting broad oncologic applications.
Market Overview
The global immunotherapy market, driven by expansion in oncology treatment, reached approximately $50 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of about 10% through 2027. Nivolumab accounts for a significant share within this segment, with sales totaling $8.4 billion in 2022.
Key Market Drivers
- Expanding FDA approvals for additional indications.
- Growing prevalence of target cancers.
- Rising adoption in combination therapies.
- Increased demand for personalized immunotherapy.
Competitive Landscape
Main competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), and durvalumab (Imfinzi). Among these, Keytruda leads sales with $21.5 billion in 2022, holding approximately 46% of the immunotherapy market share.
Geographical Market Breakdown
| Region |
Market Share (2022) |
Growth Rate (CAGR 2022-2027) |
| North America |
55% |
9% |
| Europe |
25% |
10% |
| Asia-Pacific |
15% |
12% |
| Rest of World |
5% |
11% |
Pricing Analysis
Current List Pricing
- Wholesale Acquisition Cost (WAC): Approximately $8,500 per 40 mg dose. Dosing is weight-based; typical patient doses range from 240 mg to 480 mg per infusion every two or three weeks.
- Price variations exist across regions and payers, with hospital outpatient departments often paying less after negotiations.
Reimbursement and Market Access
- Managed Care Plans: Reimburse based on negotiated discounts and confidential rebates.
- Medicaid/Medicare: Reimburse at set rates, leading to cost savings but variable based on region.
Cost Trends
- Price reductions have occurred due to biosimilar development in other monoclonal antibodies; however, no biosimilar for nivolumab has received FDA approval as of 2023.
- Patent exclusivity extends until at least 2028, limiting generic competition.
Price Projections (2023-2027)
| Year |
Avg. Wholesale Price (per 40 mg dose) |
Major Pricing Factors |
| 2023 |
$8,500 |
Stable; no biosimilars on market |
| 2024 |
$8,200–$8,400 |
Potential negotiations and rebates lower effective prices |
| 2025 |
$8,000–$8,300 |
Biosimilar development accelerates but unlikely to reduce list price significantly |
| 2026 |
$7,800–$8,200 |
Patent expiry; biosimilar entry may impact prices but slow rollout continues |
| 2027 |
$7,500–$8,000 |
Biosimilar competition gradually increasing; prices may decrease modestly |
Influencing Factors
- Biosimilar approvals and market entry could reduce prices by 20-30%, though uptake depends on payer acceptance.
- R&D for novel combination therapies or new indications might sustain the pricing if demand increases.
- Policy regulations and international pricing pressures are likely to press down pricing margins.
Regulatory and Patent Considerations
- Patent protections until 2028 (US and EU), with some patent extensions possible.
- Biosimilar development has progressed, but FDA approval remains pending; approved biosimilars could alter market dynamics significantly.
Summary Table
| Aspect |
Data/Insight |
| Market Size (2022) |
$8.4 billion (Nivolumab global sales) |
| Main Competitors |
Pembrolizumab, atezolizumab, durvalumab |
| Key Indications |
Melanoma, NSCLC, renal cell carcinoma |
| Price (2023) |
Approximate list price: $8,500 per 40 mg dose |
| Patent Expiry |
2028 (subject to extensions) |
| Biosimilar Entry |
Pending FDA approval; potential entry 2025–2026 |
Key Takeaways
- Nivolumab (NDC 82009-0040) remains a dominant immunotherapy agent with high market penetration.
- Price stability expected through 2024; gradual decline likely post-2028 with biosimilar entry.
- Market growth driven by new indications and expanded patient access.
- Competitive landscape features a few large players with significant R&D investments.
FAQs
Q1. How could biosimilar approval impact nivolumab prices?
Biosimilars could decrease list prices by 20-30%, but actual market prices depend on negotiations, rebates, and payer acceptance.
Q2. What are the primary indications for nivolumab now?
Lung cancer, melanoma, renal cell carcinoma, Hodgkin lymphoma, and several other solid tumors.
Q3. How does regional pricing differ?
US prices are higher; Europe and Asia often negotiate discounts, with some countries implementing mandatory price caps.
Q4. Are there upcoming patent expirations that could affect pricing?
Yes, patents are expected to expire in 2028 for the primary formulations, opening the market for biosimilar competition.
Q5. What is the outlook for market growth?
Continued expansion into new indications and combination regimens projects a CAGR of roughly 10% through 2027.
References
[1] MarketWatch. (2023). Immunotherapy Market Size, Share & Trends. https://www.marketwatch.com/
[2] IQVIA. (2022). Biopharmaceutical Market Data. https://www.iqvia.com/
[3] FDA. (2022). Oncology Drug Approvals. https://www.fda.gov/
[4] GlobalData. (2023). Monoclonal Antibodies Market Analysis. https://www.globaldata.com/
[5] Patentscope. (2023). Patent filings and expiry dates for Nivolumab. https://patentscope.wipo.int/
